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Abstract
 
Infection with hepatitis C virus (HCV) is a leading cause of chronic liver disease worldwide.
Little is known about how this virus is able to persist or whether this persistence might be be-
cause of its ability to alter the early innate immune response. The major HCV envelope protein
E2 has been shown to bind to CD81. Thus, HCV binding to natural killer (NK) cells could re-
sult in the cross-linking of CD81. To explore this possibility, we investigated whether cross-
linking CD81 on NK cells could alter NK cell function. CD81 cross-linking by monoclonal
antibody (mAb) specific for CD81 or by immobilized E2 have been shown to result in costim-
ulatory signals for human T cells. In this study, we show that CD81 cross-linking via immobi-
lized E2 or mAbs specific for CD81 inhibits not only non major histocompatibility complex–
restricted cytotoxicity mediated by NK cells but also interferon (IFN)-
 
 
 
 production by NK
cells after exposure to interleukin (IL)-2, IL-12, IL-15, or CD16 cross-linking. These results
show that CD81 cross-linking mediates completely different signals in NK cells versus T cells.
Importantly, these results suggest that one mechanism whereby HCV can alter host defenses
and innate immunity is via the early inhibition of IFN-
 
 
 
 production by NK cells.
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Introduction
 
Hepatitis C virus (HCV)
 
*
 
, a positive-strand RNA virus,
is the principal causative agent of parenterally transmitted
and community-acquired nonA, nonB hepatitis (1). HCV
is a major health problem, and it is estimated that HCV
 
affects 170 million people worldwide and 
 
 
 
10% of the
population in some countries (2). Infection with HCV re-
sults in subclinical chronic hepatitis in 
 
 
 
85% of infected
individuals. These individuals carry an increased risk of de-
veloping various liver diseases including cirrhosis and
hepatocellular carcinoma (3).
The exact mechanism(s) whereby HCV establishes and
maintains its persistence and the subsequent liver damage is
not well understood. It is known that both cellular and hu-
moral immune responses are present during acute and
chronic infection (4). A number of possibilities have been
proposed to explain why people infected with HCV fail to
resolve this virus despite generating both cellular and hu-
moral immune responses. One potential possibility is the
mutability of the RNA of this virus that could lead to qua-
sispecies that evade immune selection/recognition (5, 6).
Another possibility is that HCV alters or inhibits selective
but crucial immune functions. HCV-encoded proteins
such as envelope protein E2, the nonstructural protein 5A,
and core protein have been shown to have immunosup-
pressive potentials (7–9). In this regard, the innate immune
response, which is believed to play a crucial role in the
early host response to viruses and other pathogens, could
be an important target for HCV. Inhibition of the innate
immune response could allow HCV a growth advantage
that could not be completely resolved or controlled when
the adaptive immune response finally develops.
 
NK cells play an important role in the early innate host
defense against a number of pathogens. The role of NK cells
in host defense against various viral infections has been ex-
tensively investigated in humans and in different animal
models (10–15). The ability to quickly produce large
 
amounts of IFN-
 
 
 
 is believed to be a key function of NK
cells in the innate immune response. The early production
of IFN-
 
 
 
 by NK cells enable them to skew the adaptive im-
mune response to a Th1 inflammatory response. Recently, it
has been shown that IFN-
 
 
 
–mediated clearance of hepatitis
B virus (HBV) can occur in the liver of infected chimpan-
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zees before the accumulation of T cells and that this could
be a consequence of NK cell activation (16). The possibility
that HCV might be able to alter NK cell functions and thus
the innate immune response has not been fully explored.
In this study, we have investigated whether cross-linking
CD81 on NK cells can alter NK cell function. The major
HCV envelope protein E2 has been shown to bind to
CD81 (17). Thus, HCV binding to NK cells could result in
the cross-linking of CD81. CD81 cross-linking by immo-
bilized E2 or mAb specific for CD81 have been shown to
result in costimulatory signals for human T cells (18–20). In
contrast, in this study, we show that CD81 cross-linking
via immobilized E2 or mAb specific for CD81 can inhibit
IFN-
 
 
 
 production by NK cells after exposure to IL-2, IL-
12, IL-15, or CD16 cross-linking. These results show for
the first time that CD81 cross-linking mediates different
signals in NK cells than in T cells. More importantly, these
results suggest that one mechanism whereby HCV can alter
host defenses and innate immunity is via the early inhibi-
tion of NK cell production of IFN-
 
 
 
.
 
Materials and Methods
 
Reagents and Antibodies. Listeria monocytogenes
 
 (strain 506;
American Type Culture Collection) was used in experiments,
described below, to stimulate PBMCs obtained from healthy
volunteers. Bacteria were grown and prepared as described pre-
viously (18). The FITC- or PE-conjugated mouse mAbs
against human CD3, CD4, CD8, TCR-
 
 
 
/
 
 
 
, TCR-
 
 
 
/
 
 
 
,
CD19, CD14, CD16, CD56, and isotype-matched control an-
tibodies (Caltag) were used for flow cytometric analysis. In
some experiments, FITC-conjugated goat anti–mouse IgG, ob-
tained from Becton Dickinson, was used as the secondary anti-
body. Purified mouse mAb against human CD81 (clone JS-81)
was purchased from BD PharMingen. HCV envelope protein
E2 and its specific anti-E2 mAb (291A2) were provided by
Chiron Corp. and have been described previously (17). The
antibody cocktails and other reagents required for purifying
human NK cells, CD4
 
 
 
, or CD8
 
 
 
 T cells were obtained from
StemCell Technologies.
 
Generation/Purification of TCR-
 
  
 
 
 
 T Cells and NK Cells.
 
TCR-
 
  
 
 
 
 T cells were expanded from PBMCs using 
 
Listeria
monocytogenes
 
 as described previously (18). Lymphocyte cultures
shown to contain high numbers of TCR-
 
  
 
 
 
 T cells, as verified
by flow cytometry, were then used for purifying TCR-
 
  
 
 
 
 T
cells by negative selection using a magnetic column system developed
by StemCell Technologies, Inc. Briefly, 
 
 
 
5 
 
 
 
 10
 
7
 
 lymphocytes
were suspended in 1 ml of PBS, pH 7.4, supplemented with 2%
FCS. This suspension was then incubated with 100 
 
 
 
l of an anti-
body cocktail containing antibodies specific for monocytes, B cells,
and T cells bearing CD4 or CD8. This suspension was incubated
on ice for 30 min. After an additional incubation with 60 
 
 
 
l of
magnetic colloid on ice for 30 min, the cell suspension was loaded
onto a magnetic column for separation by gravity. The antibody-
labeled cells were retained in the column, whereas the unlabeled
cells were collected in the flow-through. For purification of NK
cells from freshly obtained PBMCs, the same negative selection
method was used, except that an antibody cocktail was made spe-
cifically to enrich human NK cells. Cells obtained using the above
strategies contained highly purified TCR-
 
  
 
 
 
 T cells (
 
 
 
95%
TCR-
 
  
 
 
 
) or NK cells (
 
 
 
95% CD56
 
 
 
, CD3
 
 
 
, TCR-
 
  
 
 
 
).
 
Immobilized E2 and Antibody and Cell Stimulation.
 
The ef-
fects of CD81 cross-linking on the activation of T cells versus
NK cells were investigated using a microtiter culture system. Mi-
crotiter plates (EIA/RIA plate; Corning Inc.) were coated in so-
dium bicarbonate buffer, pH 8.2, with one of the following: (i)
isotype-matched control antibody; (ii) anti-CD3 antibody (0.5
 
 
 
g/ml) or anti-CD16 (0.5 
 
 
 
g/ml); (iii) anti-CD81 mAb (5 
 
 
 
g/
ml) or immobilized E2; or (iv) a mixture of anti-CD3 plus anti-
CD81 or immobilized E2, or anti-CD16 plus anti-CD81 or im-
mobilized E2. The plates were incubated overnight at 4
 
 
 
C, and
washed three times with PBS. For immobilizing E2 onto micro-
titer wells, wells were first coated with anti-E2 mAb (5 
 
 
 
g/ml) as
described previously. These wells were then washed and exposed
to recombinant HCV E2 protein (1 
 
 
 
g/ml). These wells were
then incubated at 37
 
 
 
C for 2 h and then washed with PBS. To
determine the effect of CD81 cross-linking on the cytokine pro-
duction, 10
 
5
 
 T cells or NK cells in a total volume of 200 
 
 
 
l per
well were cultured in wells coated as described previously and in
the presence of 100 U/ml of IL-2. After 18 h, supernatants were
collected and assessed for IFN-
 
 
 
 levels by ELISA.
 
Detection of IFN-
 
 
 
.
 
The IFN-
 
 
 
 levels present in culture su-
pernatants were assessed by ELISA as described previously (18,
20). Both capture mAb and biotinylated detection mAb for human
IFN-
 
 
 
 were purchased from Becton Dickinson and BD PharMin-
gen, and used at the concentrations recommended by the manu-
facturer. Various concentrations of recombinant IFN-
 
 
 
, ranging
from 50,000 to 50 pg/ml, were included in the assay as the stan-
dard. Avidin-conjugated peroxidase and the chromogenic sub-
strate 
 
O
 
-phenylenediamine dihydrochloride were obtained from
Sigma-Aldrich. Spectrophotometer analysis was performed at 405
nm wavelength on an E
 
MAX
 
 spectrophotometer (Molecular De-
vices) using Softmax Pro software (Molecular Devices). The levels
of IFN-
 
 
 
 were expressed as the means 
 
 
 
 SD of duplicate samples.
 
Flow Cytometric Analysis.
 
The phenotypic characterization of
lymphocyte preparations was determined using standard one- or
two-color flow cytometric analysis using a FACScan™ flow cy-
tometer (Becton Dickinson). Briefly, aliquots of cells were
stained with a panel of FITC- or PE-conjugated mAb specific to
various lymphocyte surface proteins for 30 min at 4
 
 
 
C. After
washing with PBS supplemented with 2% FCS, the cells were
fixed with 0.5 ml paraformaldehyde in PBS, and analyzed by the
flow cytometer. Isotype-matched antibodies were included in all
flow cytometric analysis.
 
Cytotoxicity Assay.
 
The standard 4-h chromium-51 release
assay was used to assess the potential effect of CD81 cross-linking
on the cytolytic activities of NK cells. Human K-562 tumor cells
and Burkitt lymphoma cells (Daudi) were used as target cells for
freshly isolated NK cells and IL-2–activated NK cells, respec-
tively. Briefly, effector cells at varying concentrations were incu-
bated 30 min at 37
 
 
 
C in microtiter wells that had been precoated
with either immobilized E2 or anti-CD81. 
 
51
 
Cr-labeled target
cells (10
 
4
 
) were then added to each well. After an additional 4-h
incubation, aliquots of culture supernatants were harvested and
the percentage specific lysis determined. In some experiments
immobilized anti-CD56 antibody was also included as an addi-
tional control for assessing NK cell–mediated cytotoxicity. Spon-
taneous releases for both target cells never exceed 15%.
 
Results
 
Cross-Linking of CD81 Inhibits IFN-
 
 
 
 Productions by IL-2–,
IL-12–, or IL-15–stimulated NK Cells.
 
NK cells pro-
duce IFN-
 
 
 
 after exposure to a number of different cyto- 
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kines (15). In initial experiments we investigated whether
cross-linking CD81 on NK cells would alter IFN-
 
 
 
 pro-
duction after exposure to IL-2. NK cells were placed in
microtiter wells containing different immobilized antibod-
ies or E2 and then immediately exposed to varying concen-
trations of IL-2. Results from a representative experiment
are presented in Fig. 1. The ability of NK cells to produce
IFN-
 
 
 
 in response to IL-2 was dramatically inhibited upon
CD81 cross-linking by either immobilized E2 or anti-
CD81 antibody. No inhibition of IL-2–induced IFN-
 
 
 
production was observed when NK cells were exposed to
microtiter wells coated with an isotype-matched control
antibody (IgG1) or anti-E2. Additionally, no inhibition was
observed when NK cells were exposed to immobilized an-
tibody specific for CD56, indicating that the inhibition was
unique for CD81 cross-linking.
IL-12 and IL-15 are two cytokines believed to play a
crucial role in skewing the T cell response to a Th1 cyto-
kine profile via the stimulation of IFN-
 
 
 
 production by NK
cells (21, 22). Thus, the effect of CD81 cross-linking on
IL-12– versus IL-15–mediated activation of NK cells was
also investigated. Results from a representative experiment
are shown in Fig. 2. Cross-linking of CD81 by either im-
mobilized E2 or anti-CD81 resulted in a significant reduc-
tion in IFN-
 
 
 
 production by IL-12– or IL-15–activated
NK cells.
 
Differential Effects of CD81 Cross-Linking on NK Cell Acti-
vation versus T Cell Activation.
 
CD16 is a low-affinity IgG
receptor (Fc
 
 
 
RIII) that is expressed primarily on NK cells
(23). Cross-linking of CD16 on NK cells has been shown
to activate NK cells with regards to enhanced cytokine
production and cytolytic activity (24). To further investi-
gate the inhibitory actions of CD81 cross-linking on NK
cell functions, we investigated whether CD81 cross-linking
also inhibited NK cell activation via CD16 cross-linking.
Since the cross-linking of CD81 on T cells results in an en-
hanced proliferative response and an enhancement in cy-
tokine production after CD3 cross-linking (18–20), NK
cells and T cells appear to differ significantly with regards to
the consequences of CD81 cross-linking. To verify and
further explore this interesting difference, we assessed T
cells and NK cells in parallel for the effects of CD81 cross-
linking following the cross-linking of CD3 on T cells ver-
sus CD16 on NK cells. To address this question, NK cells,
TCR-
 
  
 
 
 
 T cells, and TCR-
 
  
 
 
 
 T cells were exposed to
varying combinations of immobilized E2 or anti-CD81 and
Figure 1. Cross-linking of CD81 significantly
inhibits IL-2–mediated IFN-  production by NK
cells. Purified NK cells (105 cells per well) were
cultured in microtiter plates that were precoated
with anti-CD81 (5  g/ml), anti-CD56 (5  g/ml),
immobilized E2 (anti-E2 (5  g/ml)/E2 (1  g/ml)
complex), or anti-E2 (5  g/ml). Each culture con-
tained 200  l of medium with or without supple-
mented IL-2 (100 U/ml). Supernatants were col-
lected after 18 h and assessed for IFN-  levels by
ELISA. The amounts of IFN-  are presented as
mean (pg/ml)   SD of duplicate samples. Data are
representative of five independent experiments us-
ing different donors.
Figure 2. Cross-linking of CD81 significantly inhib-
its IL-12– or IL-15–mediated IFN-  production by
NK cells. Purified NK cells (105 cells per well) were
cultured in microtiter plates that were precoated with
control IgG1 5  g/ml antibody, 5  g/ml anti-CD81,
5  g/ml anti-E2, or immobilized E2 (5  g/ml anti-
E2/1  g/ml E2 complex). Each culture contained 200
 l of medium supplemented with either IL-12 (500
U/ml) or IL-15 (5 U/ml). Supernatants were collected
after 18 h and assessed for IFN-  levels by ELISA. The
amounts of IFN-  are presented as mean (pg/ml)  
SD of duplicate samples. Data are representative of
three independent experiments using different donors. 
46
 
Inhibition of NK Cell Function via CD81 Cross-Linking
 
assessed for IFN-
 
 
 
 production at 18 h of culture. As shown
in Fig. 3 A and B the simultaneous cross-linking of CD81
and CD3 resulted in an enhanced production of IFN-
 
 
 
 by
TCR-
 
  
 
 
 
 and TCR-
 
  
 
 
 
 T cells. These results are identi-
cal to previously published findings (18–20). In striking
contrast, when CD81 was cross-linked along with CD16
cross-linking (Fig. 3 A) or IL-2 stimulation (Fig. 3 B) a sig-
nificant inhibition of IFN-
 
 
 
 production by NK cells was
observed. As seen in Fig. 4, these differences were not due
to potential differences in the stimuli used for activation of
NK cells versus T cells since identical results were also ob-
served when both TCR-
 
  
 
 
 
 T cells and NK cells were
assessed for IFN-
 
 
 
 production after IL-2 stimulation.
Cross-linking CD81 on T cells or NK cells with either im-
mobilized E2 or mAb specific for CD81 yielded equivalent
results. These results show that instead of providing costim-
ulatory signals, as seen with T cells, CD81 cross-linking on
 
NK cells induces negative regulatory signals that inhibit or
downregulate NK cell activation.
 
Cross-Linking of CD81 Inhibits Cytolytic Activity of NK
Cells.
 
To determine whether cross-linking of CD81 can
modulate NK cell–mediated cytotoxicity, freshly isolated
and purified NK cells were incubated for 30 min in micro-
titer wells precoated with one of the following: (i) isotype
matched control IgG1; (ii) anti-CD81; (iii) anti-CD56; (iv)
anti-E2; or (v) immobilized E2. Non-MHC–restricted cy-
totoxic activity was then assessed against K562 tumor cells.
A representative experiment is presented in Fig. 5. No al-
teration in NK cell cytotoxic activity was observed when
CD56 was cross-linked on NK cells or when NK cells
were exposed to immobilized control IgG1 or mAb to E2.
However, the cross-linking of CD81 on NK cells via ei-
ther immobilized E2 or anti-CD81 resulted in a significant
reduction in the cytolytic activity. Identical results were
Figure 3. Differential effects of CD81 crosslink-
ing on the activation of NK cells versus TCR-  +
or TCR-  + T cells. (A) Purified NK cells,
TCR-  + T cells, or TCR-  + T cells were cul-
tured in wells (105 per well) precoated with follow-
ing antibodies: (i) 0.5  g/ml anti-CD16 (NK cells)
or anti-CD3 (T cells); (ii) anti-CD16 plus anti-E2
(5  g/ml) for NK cells or anti-CD3 plus anti-E2
for T cells; or (iii) anti-CD16 plus immobilized
E2 (1  g/ml anti-E2/E2) for NK cells, or anti-
CD3 plus immobilized E2 (anti-E2/E2) for T cells.
TCR-  + T cells were derived from bacteria-
expanded cultures, as described in Materials and
Methods. TCR-  + T cells were derived from
anti–CD3- or ConA-activated PBL. Each culture
contained 200  l of medium supplemented with
IL-2 (100 U/ml). Supernatants were collected after
18 h and assessed for the IFN-  levels by ELISA.
IFN-  levels are presented as mean (pg/ml)   SD
of duplicate samples. Data are representative of two
independent experiments using different cell prepa-
rations. (B) Purified NK cells or TCR-  + T cells
were cultured in wells precoated with varying con-
centrations of antibody specific for CD81. For NK
cells, IL-2 (100 U/ml) was added to each well. For
T cells, wells were precoated with varying concen-
trations of anti-CD81 along with a constant
amount of anti-CD3 (0.5  g/ml). Culture super-
natants were collected after 18 h and assessed for
IFN-  levels by ELISA. IFN-  levels are presented
as mean (pg/ml)   SD of duplicate samples. Data
presented is derived from one of two independent
experiments. (*P   0.05; **P   0.01; Student’s t test).47 Tseng et al.
also observed when assessing IL-2–activated NK cells (data
not presented).
Discussion
NK cell production of IFN-  and/or the recognition of
virally infected cells are believed to play important roles in
the innate immune response to virus infections. These
functions are an important aspect of the immediate re-
sponse of the host to virus and are believed to control the
initial virus infection so that levels of virus are not too high
or overwhelming for when the adaptive immune response
develops. The production of IFN-  by NK cells not only
directly inhibits virus replication but more importantly, can
also skew the Th cell response to a Th1 profile (15, 21).
The importance of NK cells in host defense to different vi-
ruses has been extensively studied using animal models
where NK cell depletion or deficiency results in a signifi-
cant increase in the sensitivity of the animal to a number of
viruses (15). In humans, low NK cell function has been
linked with increased human susceptibility to HSV, Ep-
stein-Barr virus, human cytomegalovirus, and HIV (10, 12,
14, 15). Additionally, NK cell function has also been
shown to be decreased significantly in chronic HCV
patients, compared with noninfected individuals, even
though the numbers of circulating NK cells were compara-
ble between these two groups of individuals (25). The pos-
sibility that HCV might alter NK cell function is also sug-
gested because the exposure of PBMCs from healthy
individuals to virus containing serum obtained from HCV-
infected individuals resulted in the inhibition of NK-medi-
ated cytotoxicity (25). Our results show that the major
HCV envelope protein E2 can inhibit, via cross-linking
CD81, NK cell production of IFN-  and the nonMHC-
restricted cytotoxic activity of these cells. Pileri and col-
leagues (17) have previously shown that HCV particles can
bind human CD81 and that this binding takes place with
high affinity and through the larger of the two extracellular
loops of this protein. Thus, there is a distinct possibility that
HCV could interact with NK cells via E2:CD81 interac-
tions that could result in CD81 cross-linking, resulting in
alterations in NK cell functions. This could have a poten-
tially important impact on the initial host response, the in-
nate immune response, to HCV infection and on the ki-
netics and magnitude of the T cell and B cell immune
responses that later develop. Insufficient production of
IFN-  by NK cells in response to IL-12 and IL-15 activa-
tion could alter the development of Th1 responses and fa-
vor the development of enhanced Th2 responses. Interest-
ingly, an imbalance between Th1 versus Th2 responses has
recently been described in chronic HCV infected individu-
als (26, 27). Specifically, the defect in the production of
Th1 cytokines with an enhanced Th2 response has been
proposed to be responsible for the persistent virus and dis-
ease in chronic HCV infections. Thus, alterations in NK
cell function could set up a situation where the virus might
have an initial growth advantage that could then lead to the
development of a chronic and persistent infection that
Figure 4. CD81 inhibits IL2 activation of NK cells and TCR-  + T
cells. Purified NK cells or TCR-   T cells were cultured in wells (105
cells per well) either untreated or precoated with control IgG1 antibody (5
 g/ml) or anti-CD81 (5  g/ml). Each culture contained 200  l of me-
dium with or without supplemented IL-2 (100 U/ml). Supernatants were
collected after 18 h and assessed for IFN-  levels by ELISA. The levels of
IFN-  are presented as mean (pg/ml)   SD of duplicate samples. Data are
representative of three independent experiments using different donors.
Figure 5. CD81 cross-linking inhibits the cytotoxic
activities of fresh NK cells. The standard 4-h chromium
release assay was used to assess NK cell–mediated cyto-
toxicity. Varying numbers of freshly isolated NK cells
were cultured in microtiter wells precoated control IgG1,
anti-CD81, or anti-CD56 antibody at 1  g/ml of each
antibody, 5  g/ml anti-E2, or immobilized E2 (1  g/ml
anti-E2/E2) for 30 min before addition of 51Cr-labeled
K-562 (104 cells per well). Effector:target cell ratios of 20,
10, 5, and 2.5 were used in each experiment. Spontaneous
releases for K-562 were always below 10%. Specific lysis is
presented as mean percentage   SD of duplicate samples.
Data are representative of six independent experiments us-
ing different cell preparations.48 Inhibition of NK Cell Function via CD81 Cross-Linking
could not be completely cleared by the T cell and B cell re-
sponses. Consistent with the above possibility are the re-
cent findings that IFN- –mediated clearance of HBV can
occur in the liver of infected chimpanzees before the accu-
mulation of T cells (16). It was proposed that NK cell–
derived IFN-  might be responsible for this early noncyto-
pathic anti-HBV activity.
CD81 is a member of the tetraspan superfamily
(TM4SF) of proteins (28). Results from a number of stud-
ies suggest that TM4SF proteins are components of large
molecular complexes. These complexes or molecular net-
works and associated proteins have been suggested to be
surface organizers or facilitators that connect different mol-
ecules of the cell surface and therefore couple different
functions (29). Cross-linking of different TM4SF proteins
via different mAbs has been shown to regulate a number of
functions including adhesion, activation, proliferation, dif-
ferentiation, and motility. CD81 has been shown to be as-
sociated with other members of the TM4SF, the integrin
 4 1, HLA-DR, CD4, CD8, CD21, and CD19 (28, 29).
However, what molecules might be associated with CD81
on NK cells is not known. Cross-linking of CD81 has
been shown to result in costimulatory signals for both T
cells and B cells (18–19, 30). Recently, we have found that
immobilized E2 can act like mAb specific for CD81 with
regards to providing costimulatory signals for human T
cells (18–20). The molecular mechanism(s) involved in
CD81 signaling of T cells and B cells is not known. In this
study, we show that cross-linking CD81 on NK cells re-
sults in inhibition of cytokine production and nonMHC-
restricted cytotoxic activity. Thus, cross-linking of CD81
on NK cells results in a completely different signaling cas-
cade and instead of giving a costimulatory signal, as with T
cells, it gives an inhibitory signal. Whether this is due to
CD81 being associated with NK cell inhibitory receptors is
currently under investigation. Regardless of the mecha-
nism, these results indicate that NK cells differ significantly
from T cells or B cells with regards to CD81 cross-linking.
The biological significance of the differential effects of
CD81 cross-linking on the activation of T cells versus NK
cells in the course of HCV infection remains to be deter-
mined. However, this difference could have important bi-
ological consequences for how HCV might regulate the
innate and adaptive immune responses.
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